Hissey Kientz Announced that it Has Filed a Lawsuit in California on Behalf
(PRWEB) December one, 2007 The law firm of Hissey Kientz has announced that it's filed a lawsuit in California state court against Advanced Medical Optics on behalf of 3 girls who suffered eye injury and vision loss as a results of a severe eye infection (Case No. 07CC01413, 07CC01414, 07CC01415). The lawsuit alleges that the 3 developed a severe variety of eye infection called Acanthamoeba keratitis as a results of using Advanced Medical Optics' Complete Moisture and contact lens resolution. AMO Complete was recalled by Advanced Medical Optics on could twenty five, 2007, once the CDC determined that more than 1/2 the patients it interviewed had developed the attention infection Acanthamoeba keratitis once using the resolution. The CDC has identified a minimum of 138 Acanthamoeba keratitis infections up to now. Doctors estimate that about 1/2 these patients could eventually need a cornea transplant to correct the injury to their eyesight from infection. One of the 3 girls was diagnosed with an Acanthamoeba keratitis infection in January 2007 once having used AMO Complete. In her lawsuit, she says that she has suffered permanent corneal scarring as a results of her Acanthamoeba keratitis infection, and will need a cornea transplant within the future to repair the injury to her eyesight. Her doctor says that even with corrective lenses, she is going to never be ready to regain traditional vision attributable to the scarring on her cornea. The lawsuit alleges that the corporate continued to sell generic seroquel xr from canada and market AMO Complete despite proof that it might increase a patient's risk of developing an Acanthamoeba keratitis infection. The first proof of a link between AMO Complete and Acanthamoeba keratitis was uncovered in 2004, when doctors at a hospital in Illinois treated quite a dozen patients with this rare form of infection. Normally they would receive only 1 or 2 cases per year. After reporting this outbreak to the CDC, a preliminary investigation revealed that 13 eye canadian pharmacy seroquel centers across
Form for news memo
WASHINGTON – The Department of Justice nowadays announced a $520 million civil settlement with pharmaceutical company AstraZeneca LP and AstraZeneca prescription drugs, LP (AstraZeneca) to resolve allegations created beneath the civil False Claims Act that AstraZeneca illegally marketed the antipsychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration (FDA). Such unapproved uses are referred to as “offlabel” uses as a result of they're not included within the drug’s FDA approved product label. United States Attorney General Eric Holder, Assistant Attorney General for the Civil Division Tony West, and us Attorney Michael L. Levy of the japanese District of Pennsylvania announced the settlement nowadays. They were joined by Special AgentinCharge Nick DiGiulio of the workplace of Inspector General of the Department of Health and Human Services. AstraZeneca, headquartered in Wilmington, Delaware, signed a civil settlement to resolve allegations that by selling Seroquel for unapproved uses, the corporate caused false claims for payment to be submitted to federal insurance programs together with Medicaid, Medicare, and TRICARE programs, and to the Department of Veterans Affairs, the Federal Employee Health Benefits Program, and therefore seroquel xr in canadathe Bureau of Prisons. The civil settlement agreement provides that AstraZeneca pays up to $520 million to the national and therefore the states to resolve civil allegations originally brought in a very lawsuit under the
provisions of the federal False Claims Act and numerous state False Claims Act statutes. The national can receive $301,907,007 from the civil when will seroquel be generic settlement. The *point4*
留言列表
